APYX vs SSKN

For growth investors, Apyx Medical Corporation (APYX) is the stronger pick with 9.

9% revenue growth year-over-year, versus 0. 6% for STRATA Skin Sciences, Inc. (SSKN). Analysts rate Apyx Medical Corporation (APYX) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Apyx Medical Corporation (APYX) delivered a total return of -68.

7%, compared to -99. 2% for STRATA Skin Sciences, Inc. (SSKN). Over 10 years, the gap is even starker: APYX returned -54. 9% versus SSKN's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), STRATA Skin Sciences, Inc.

(SSKN) is the lower-risk stock at -0. 24β versus Apyx Medical Corporation's 1. 96β — meaning APYX is approximately -903% more volatile than SSKN relative to the S&P 500. On balance sheet safety, Apyx Medical Corporation (APYX) carries a lower debt/equity ratio of 3% versus 3% for STRATA Skin Sciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Apyx Medical Corporation (APYX) is pulling ahead at 9.

9% versus 0. 6% for STRATA Skin Sciences, Inc. (SSKN). On earnings-per-share growth, the picture is similar: Apyx Medical Corporation grew EPS 59. 1% year-over-year, compared to 16. 1% for STRATA Skin Sciences, Inc.. Over a 3-year CAGR, APYX leads at 5. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Apyx Medical Corporation (APYX) is the more profitable company, earning -21.

2% net margin versus -30. 1% for STRATA Skin Sciences, Inc. — meaning it keeps -21. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: APYX leads at -12. 2% versus -27. 6% for SSKN. At the gross margin level — before operating expenses — SSKN leads at 56. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, STRATA Skin Sciences, Inc.

(SSKN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 24)). Apyx Medical Corporation (APYX) carries a higher beta of 1. 96 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SSKN: -99. 7%, APYX: -54. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.